Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Fate Therapeutics

General information

Main focus: Allogeneic natural killer cell therapies

Company stage: Clinical

Diseases: Acute myleoid leukaemia (AML), B-cell lymphoma (BCL), chronic lymphocytic leukaemia (CLL), multiple myeloma (MM), solid tumours

Genome editing tool: CRISPR-Cas9

Funding stage: Public (NASDAQ:FATE)

Location: San Diego, CA, USA



Partners: Janssen Pharmaceuticals, Ono Pharma, Inscripta

Fate Therapeutics is a publicly-traded, clinical-stage, biopharmaceutical company mainly focusing on the development of first-in-class cellular immunotherapies. The company applies an in house iPSC and gene-editing platform to develop T- and natural killer cell therapies targeting blood cancers and solid tumours.


HashtagFate Therapeutics, Inc.

Company: Fate Therapeutics
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine